<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534469</url>
  </required_header>
  <id_info>
    <org_study_id>99040</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-99040</secondary_id>
    <secondary_id>CDR0000564772</secondary_id>
    <nct_id>NCT00534469</nct_id>
  </id_info>
  <brief_title>Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission</brief_title>
  <official_title>Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients &lt;/=60 Years of Age Using Busulfan/Fractionated Total Body Irradiation (FTBI) and VP16 as the Preparative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of&#xD;
      cancer cells by stopping them from dividing or killing them. After treatment, stem cells are&#xD;
      collected from the patient's blood and/or bone marrow and stored. More chemotherapy and&#xD;
      radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem&#xD;
      cells are then returned to the patient to replace the blood-forming cells that were destroyed&#xD;
      by the chemotherapy and radiation therapy. Giving aldesleukin after transplant may help keep&#xD;
      cancer cells from coming back after transplant.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving busulfan and&#xD;
      etoposide together with total-body irradiation followed by autologous stem cell transplant&#xD;
      and aldesleukin works in treating patients with acute myeloid leukemia in first remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the efficacy and toxicity of a preparative regimen comprising busulfan,&#xD;
           etoposide, and fractionated total-body irradiation followed by autologous stem cell&#xD;
           transplantation and aldesleukin after treatment with consolidation therapy comprising&#xD;
           high-dose cytarabine with or without idarubicin in patients with acute myeloid leukemia&#xD;
           in first remission.&#xD;
&#xD;
        -  To estimate the long-term disease-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  To further evaluate the effect of prognostic factors (e.g., cytogenetics, WBC at&#xD;
           presentation, and number of courses of induction therapy required to achieve remission)&#xD;
           on the outcome of autologous stem cell transplantation and targeted busulfan dose.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Consolidation therapy: Patients who received prior consolidation therapy are evaluated&#xD;
           to determine the need for additional consolidation therapy. Patients who have not&#xD;
           received prior consolidation therapy receive high-dose cytarabine IV over 3 hours every&#xD;
           12 hours on days 1-4 and idarubicin* IV over 5-10 minutes on days 1-3.&#xD;
&#xD;
      NOTE: *Patients with good risk cytogenetics t(8;21), inv(16), or t(16;16) or patients who&#xD;
      received &gt; 200 mg/mÂ² of anthracycline do not receive idarubicin.&#xD;
&#xD;
        -  Stem cell collection: All patients receive filgrastim (G-CSF) IV or subcutaneously (SC)&#xD;
           twice daily beginning 7 days after completion of high-dose cytarabine and continuing&#xD;
           until peripheral blood stem cell (PBSC) collection is completed. Patients who do not&#xD;
           have an adequate number of PBSCs collected also undergo bone marrow collection.&#xD;
&#xD;
        -  Preparative regimen: Patients receive busulfan IV over 2 hours on days -13 and -11 to -7&#xD;
           and etoposide IV on day -2. Patients also undergo fractionated total-body irradiation on&#xD;
           days -6 to -3 for a total of 8-10 fractions.&#xD;
&#xD;
        -  Autologous stem cell transplantation: Patients undergo autologous stem cell&#xD;
           transplantation using PBSCs (with or without bone marrow) on day 0. Patients receive&#xD;
           G-CSF IV or SC daily beginning on day 5 and continuing until blood counts recover.&#xD;
&#xD;
        -  Interleukin therapy: Within 100 days post-transplantation, patients receive aldesleukin&#xD;
           IV continuously on days 1-4 and 9-18.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 8, 2000</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of preparative therapy as measured by 2- and 5-year disease-free survival</measure>
    <time_frame>5 years post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity of preparative therapy</measure>
    <time_frame>Day 100 post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of administration and ability to tolerate aldesleukin after transplantation</measure>
    <time_frame>5 years post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of cytogenetics, WBC at presentation, targeted busulfan dose, and number of courses of induction therapy required to achieve remission on possible prognostic factors for relapse, disease-free survival, and overall survival</measure>
    <time_frame>5 years post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HD ARA-C with Idarubicin Consolidation, Busulfan/FTBI/VP16/PSC/BMT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HD ARA-C Consolidation, Busulfan/FTBI/VP16/PSC/BMT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow transplantation</intervention_name>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <arm_group_label>HD ARA-C with Idarubicin</arm_group_label>
    <arm_group_label>HD ARA-C without Idarubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acute myeloid leukemia (AML)&#xD;
&#xD;
               -  FAB types M0-2 and M4-M7&#xD;
&#xD;
                    -  No M3 disease&#xD;
&#xD;
          -  In first complete hematological remission as confirmed by marrow aspiration and biopsy&#xD;
&#xD;
               -  No cytogenetic abnormality in the remission marrow&#xD;
&#xD;
               -  In complete remission for less than 6 months&#xD;
&#xD;
                    -  Patients who have been in complete remission for more than 6 months may be&#xD;
                       eligible upon approval of the principal investigator&#xD;
&#xD;
          -  No prior myeloproliferative disorder (e.g., chronic myeloid leukemia, myelofibrosis,&#xD;
             essential thrombocytosis, or polycythemia vera)&#xD;
&#xD;
          -  No prior myelodysplasia or secondary leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  FEV_1 &gt; 60%&#xD;
&#xD;
          -  DLCO &gt; 50%&#xD;
&#xD;
          -  Cardiac ejection fraction â¥ 50%&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  No severe chronic medical or psychological illness that, in the judgement of the&#xD;
             principal investigator, would jeopardize the ability of the patient to tolerate&#xD;
             aggressive chemotherapy&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior consolidation therapy allowed&#xD;
&#xD;
          -  No concurrent use the following medications during aldesleukin therapy :&#xD;
&#xD;
               -  Corticosteroids (including blood product &quot;pre-meds&quot;)&#xD;
&#xD;
               -  Pentoxifylline&#xD;
&#xD;
               -  IV or intrathecal methotrexate&#xD;
&#xD;
               -  IV immunoglobulin&#xD;
&#xD;
               -  Other cytokines or growth factors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony S. Stein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

